Pituitary-Dependent Cushing's Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PTT003 MIFTS: 46	Pituitary-Dependent Cushing's Disease Categories: Endocrine diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Pituitary-Dependent Cushing's Disease

MalaCards integrated aliases for Pituitary-Dependent Cushing's Disease:

Name: Pituitary-Dependent Cushing's Disease ¹¹ ¹⁴ ¹⁶ ⁷¹

Pituitary-Dependent Cushing Disease ¹¹ ³¹ ³³

Pituitary Acth Hypersecretion ⁴³ ³³

Acth- [adrenocorticotropic Hormone] Secreting Pituitary Adenoma ³³

Cushing Syndrome or Disease, Pituitary-Dependent ³³

Pituitary-Dependent Hyperadrenocorticism ³³

Pituitary-Dependent Cushings Disease ⁵³

Pituitary-Dependent Hypercorticalism ³³

Overproduction of Pituitary Acth ³³

Corticotroph Pituitary Adenoma ³³

Itsenko-Cushing Syndrome ³³

Suprarenogenic Syndrome ³³

Overproduction of Acth ¹¹

Pituitary Basophilism ³³

Cushings Basophilism ³³

Cushing's Syndrome 3 ³³

Cushing's Disease ³³

Cushing Disease ³³

Itsenko Disease ³³

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Endocrine, nutritional and metabolic diseases

Disorders of other endocrine glands

Cushing syndrome

Pituitary-dependent Cushing disease

ICD11: ³³

Endocrine, nutritional or metabolic diseases

Endocrine diseases

Disorders of the adrenal glands or adrenal hormone system

Cushing syndrome

Pituitary-dependent Cushing disease

External Ids:

Disease Ontology ¹¹ DOID:3946

MeSH ⁴³ D047748

NCIt ⁴⁹ C113210

SNOMED-CT ⁶⁸ 190502001

ICD10 ³¹ E24.0

EFO ¹⁶ EFO_1001110

ICD11 ³³ 380861892

UMLS ⁷¹ C0221406

Sources

Summaries for Pituitary-Dependent Cushing's Disease

MalaCards based summary: Pituitary-Dependent Cushing's Disease, also known as pituitary-dependent cushing disease, is related to pituitary adenoma 1, multiple types and acth-independent macronodular adrenal hyperplasia. An important gene associated with Pituitary-Dependent Cushing's Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are GPCR downstream signalling and Signal Transduction. The drugs Metformin and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, adrenal cortex and adrenal gland, and related phenotypes are nervous system and homeostasis/metabolism

Sources

Related Diseases for Pituitary-Dependent Cushing's Disease

Diseases related to Pituitary-Dependent Cushing's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 577)

#	Related Disease	Score	Top Affiliating Genes
1	pituitary adenoma 1, multiple types	31.9	SST PRL GH1
2	acth-independent macronodular adrenal hyperplasia	31.3	POMC MC2R CRH
3	acth-secreting pituitary adenoma	30.9	USP8 USP48 SST PRL POMC NR3C1
4	abducens palsy	30.5	PRL POMC
5	diabetes insipidus	30.2	PRL POMC GH1 CRH
6	hypoadrenocorticism, familial	30.2	POMC MC2R CRH
7	graves disease 1	30.2	TRH POMC
8	withdrawal disorder	30.2	POMC CRH
9	multiple endocrine neoplasia	30.2	SST PRL POMC
10	premature ovarian failure 7	30.2	POMC GH1 CRH
11	pituitary tumors	30.1	SST PRL GH1
12	hypokalemia	30.1	POMC NR3C1 CRH
13	central diabetes insipidus	30.1	TRH PRL POMC GH1
14	carcinoid syndrome	30.1	SST GHRH
15	glucocorticoid deficiency 1	30.1	POMC MC2R
16	hypothyroidism, congenital, nongoitrous, 4	30.0	PRL POMC GH1
17	insulin-like growth factor i	30.0	SST PRL GHRH GH1
18	inappropriate adh syndrome	30.0	PRL POMC CRH
19	acne	30.0	PRL POMC CRH
20	somatoform disorder	30.0	POMC CRH
21	amenorrhea	29.9	TRH PRL POMC CRH
22	personality disorder	29.9	PRL NR3C1 CRH
23	acth deficiency, isolated	29.9	TRH PRL POMC CRH
24	hypogonadism	29.9	PRL POMC GH1
25	skin atrophy	29.9	POMC NR3C1
26	polycystic ovary syndrome	29.9	PRL POMC GH1
27	mood disorder	29.8	TRH POMC NR3C1 CRH
28	fibrous dysplasia	29.8	SST PRL GHRH GH1
29	craniopharyngioma	29.8	TRH PRL GH1
30	intracranial hypertension	29.8	PRL POMC
31	chiasmal syndrome	29.8	SST PRL POMC
32	adrenal adenoma	29.8	POMC MC2R CRH
33	adult syndrome	29.8	POMC NR3C1 CRH
34	post-traumatic stress disorder	29.8	POMC NR3C1 CRH
35	thyroid gland medullary carcinoma	29.8	SST POMC
36	pheochromocytoma	29.8	SST PRL POMC CRH
37	glucose intolerance	29.7	SST PRL POMC GH1
38	social phobia	29.7	PRL POMC CRH
39	acute stress disorder	29.7	POMC NR3C1 CRH
40	germinoma	29.7	PRL POMC
41	substance abuse	29.7	PRL POMC CRH
42	mental depression	29.7	POMC NR3C1 CRH
43	hyperandrogenism	29.7	PRL POMC NR3C1 GH1
44	goiter	29.7	TRH SST PRL
45	multiple endocrine neoplasia, type i	29.7	SST PRL POMC GHRH
46	chromophobe adenoma	29.6	TRH PRL POMC GH1
47	prolactinoma	29.6	TRH SST PRL POMC GH1
48	empty sella syndrome	29.6	TRH PRL POMC GH1
49	major depressive disorder	29.6	TRH SST PRL POMC NR3C1 CRH
50	adrenal cortical carcinoma	29.6	POMC MC2R CRH

Graphical network of the top 20 diseases related to Pituitary-Dependent Cushing's Disease:

Sources

Symptoms & Phenotypes for Pituitary-Dependent Cushing's Disease

MGI Mouse Phenotypes related to Pituitary-Dependent Cushing's Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.09	CRH GH1 GHRH MC2R NR3C1 POMC
2	homeostasis/metabolism	MP:0005376	10.02	CRH GH1 GHRH MC2R NR3C1 POMC
3	liver/biliary system	MP:0005370	9.95	CRH GH1 GHRH NR3C1 POMC PRL
4	adipose tissue	MP:0005375	9.91	CRH GH1 GHRH MC2R NR3C1 POMC
5	growth/size/body region	MP:0005378	9.91	CRH GH1 GHRH MC2R NR3C1 POMC
6	no phenotypic analysis	MP:0003012	9.85	CRH NR3C1 POMC SST TRH
7	endocrine/exocrine gland	MP:0005379	9.76	CRH GH1 GHRH MC2R NR3C1 POMC
8	behavior/neurological	MP:0005386	9.61	CRH GH1 GHRH MC2R NR3C1 POMC
9	immune system	MP:0005387	9.23	CRH GH1 GHRH MC2R NR3C1 POMC

Sources

Drugs & Therapeutics for Pituitary-Dependent Cushing's Disease

Drugs for Pituitary-Dependent Cushing's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Metformin

Approved

Phase 4

1115-70-4, 657-24-9

4091

Liraglutide

Approved

Phase 4

204656-20-2

44147092 16134956

Pasireotide

Approved

Phase 4

396091-73-9

56841596 9941444

Somatostatin

Approved, Investigational

Phase 4

38916-34-6, 51110-01-1

53481605 16129706

Cabergoline

Approved

Phase 4

81409-90-7

54746

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

HIV Protease Inhibitors

Phase 4

protease inhibitors

Phase 4

Insulin, Globin Zinc

Phase 4

Insulin

Phase 4

Sitagliptin Phosphate

Phase 4

654671-77-9

Dipeptidyl-Peptidase IV Inhibitors

Phase 4

Incretins

Phase 4

Hormone Antagonists

Phase 4

Neurotransmitter Agents

Phase 4

Dopamine agonists

Phase 4

Dopamine Agents

Phase 4

Antiparkinson Agents

Phase 4

Ketoconazole

Approved, Investigational

Phase 3

65277-42-1, 142128-57-2

47576 3823 638701

Pharmaceutical Solutions

Phase 3

Hypoglycemic Agents

Phase 2, Phase 3

glucocorticoids

Phase 2, Phase 3

Bexarotene

Approved, Investigational

Phase 1, Phase 2

153559-49-0

82146

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Racepinephrine

Approved, Vet_approved

Phase 2

51-43-4, 329-65-7

838 5816

Benzocaine

Approved, Investigational

Phase 2

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 2

1401-55-4

16129878 16129778

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 2

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

4159 6741

Vorinostat

Approved, Investigational

Phase 2

149647-78-9

5311

Rosiglitazone

Approved, Investigational

Phase 2

122320-73-4, 155141-29-0

77999

Prednisolone hemisuccinate

Experimental

Phase 2

2920-86-7

4897

Maleic acid

Experimental, Investigational

Phase 2

110-16-7, 110-17-8

444266 444972

Adrenocorticotropic Hormone

Phase 2

Epinephryl borate

Phase 2

Neuroprotective Agents

Phase 2

Methylprednisolone Acetate

Phase 2

584547

Protective Agents

Phase 2

Histone Deacetylase Inhibitors

Phase 2

Roscovitine

Phase 2

Antiviral Agents

Phase 2

Anti-Infective Agents

Phase 2

Protein Kinase Inhibitors

Phase 2

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 1

67-97-0, 1406-16-2

5280795 10883523

Vitamins

Phase 1

Trace Elements

Phase 1

Interventional clinical trials:

(show top 50) (show all 52)

#	Name	Status	NCT ID	Phase	Drugs
1	Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters	Completed	NCT03080181	Phase 4	Pasireotide 0.6 MG/ML
2	A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly	Completed	NCT02060383	Phase 4	Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3	An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment	Active, not recruiting	NCT01794793	Phase 4	Pasireotide;Cabergoline
4	A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease	Completed	NCT02697734	Phase 3	osilodrostat;osilodrostat Placebo
5	A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease	Completed	NCT00434148	Phase 3	Pasireotide
6	Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor	Completed	NCT00889525	Phase 3	Cabergoline
7	Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease	Completed	NCT02180217	Phase 3	osilodrostat;LCI699 matching placebo
8	Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome	Completed	NCT01371565	Phase 3	Mifepristone
9	Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study	Completed	NCT01319994	Phase 2, Phase 3	Metformin;Placebo
10	A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease	Completed	NCT01374906	Phase 3	pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
11	An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).	Completed	NCT01582061	Phase 3	Pasireotide sub-cutaneous
12	An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome	Active, not recruiting	NCT03621280	Phase 3	Levoketoconazole
13	An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease	Withdrawn	NCT01925092	Phase 3	mifepristone
14	Preoperative Bexarotene Treatment for Cushing's Disease	Unknown status	NCT00845351	Phase 1, Phase 2	Bexarotene
15	Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease	Unknown status	NCT02484755	Phase 2	Gefitinib
16	Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease	Completed	NCT00171951	Phase 2	Pasireotide
17	Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)	Completed	NCT03111810	Phase 2	AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
18	A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease	Completed	NCT00088608	Phase 2	SOM230 s.c.
19	A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease	Completed	NCT01331239	Phase 2	LCI699
20	A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease	Completed	NCT02468193	Phase 2	Osilodrostat
21	A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease	Recruiting	NCT03708900	Phase 2	LCI699
22	The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease	Recruiting	NCT04339751	Phase 2	Vorinostat
23	SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome	Recruiting	NCT05307328	Phase 2	SPI-62;Placebo
24	A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease	Active, not recruiting	NCT03774446	Phase 2	Seliciclib
25	A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease	Terminated	NCT01915303	Phase 2	Pasireotide with or without cabergoline
26	An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease	Terminated	NCT00612066	Phase 2	rosiglitazone maleate
27	Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine	Terminated	NCT02160730	Phase 2	R-roscovitine
28	Prospective Non-randomised Controlled Study of Vitamin D Metabolism in Patients With Endocrine Disorders (Acromegaly, Cushing's Disease, Primary Hyperparathyroidism, Diabetes Mellitus Type 1) Treated With Cholecalciferol Bolus Dose	Completed	NCT04844164	Phase 1	Cholecalciferol 15000 UNT/ML Oral Solution
29	Prospective Observational Study of Diagnostic Yield in Cushing's Disease Using Deep Learning Based Denoising MRI	Unknown status	NCT04121988
30	Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015	Unknown status	NCT03297892
31	Cognitive Sequels of Cushing Syndrome	Unknown status	NCT02603653
32	Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease	Completed	NCT02568982
33	Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease	Completed	NCT03817840
34	Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease	Completed	NCT03346954
35	National Swedish Study in Cushing´s Disease Incidence and Outcomes	Completed	NCT02350153
36	Cognition, Steroids, and Imaging in Cushings Disease	Completed	NCT00081341
37	Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study	Completed	NCT01504399
38	The Factors Associated With the Recurrence in Patients With Cushing Disease	Completed	NCT02233335
39	Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease	Completed	NCT01459237	Early Phase 1	Acthrel
40	A Prospective, Multicenter, Randomized Controlled Study of Postoperative Thrombosis Prevention in Patients With Cushing's Disease	Recruiting	NCT04486859		LMWH/Rivaroxaban
41	Long-Term Follow-UP of Survivors of Pediatric Cushing Disease	Recruiting	NCT03831958
42	Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders	Recruiting	NCT04374721
43	Usefulness of Hair Cortisol/Cortisone Concentrations for the Monitoring of Medical Treatment in Patients With Cushing's Disease	Recruiting	NCT04201444
44	Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)	Recruiting	NCT02310269		SOM230
45	A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders	Recruiting	NCT00001595
46	Treatment Outcomes for Patients With Cushing's Syndrome: a Prospective Data Collection Study	Recruiting	NCT03364803
47	Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms: Phase III Diagnostic Evaluation Study	Recruiting	NCT03974789
48	Seoul National University Pituitary Disease Cohort Study	Recruiting	NCT03474601
49	Corticotrophin-Releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing's Disease	Not yet recruiting	NCT04569591		Acthrel
50	A Retrospective Observational Study to Evaluate the Safety and Effectiveness of Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome (LINC7)	Not yet recruiting	NCT05633953		Osilodrostat

Search NIH Clinical Center for Pituitary-Dependent Cushing's Disease

Cochrane evidence based reviews: pituitary acth hypersecretion

Sources

Genetic Tests for Pituitary-Dependent Cushing's Disease

Sources

Anatomical Context for Pituitary-Dependent Cushing's Disease

Organs/tissues related to Pituitary-Dependent Cushing's Disease:

MalaCards : Pituitary, Adrenal Cortex, Adrenal Gland, Bone, Cortex, Thyroid, Brain

Sources

Publications for Pituitary-Dependent Cushing's Disease

Articles related to Pituitary-Dependent Cushing's Disease:

(show top 50) (show all 5540)

#	Title	Authors	PMID	Year
1	[Evaluation of the accuracy of inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome]. ⁵³ ⁶²	Toth M...Racz K	17468067	2007
2	The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. ⁵³ ⁶²	Hofland LJ...Lamberts SW	15817922	2005
3	Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy. ⁵³ ⁶²	Veldman RG...Roelfsema F	11095430	2000
4	Growth hormone and prolactin are secreted more irregularly in patients with Cushing's disease. ⁵³ ⁶²	Veldman RG...Roelfsema F	10792343	2000
5	The modulation of glucocorticoid receptor content by 3-O-methyl-D-glucose transport in human mononuclear leukocyte in obesity. ⁵³ ⁶²	Guven M...Kanigur-Sultuybek G	9854680	1998
6	Differential diagnosis in cushing syndrome. Use of corticotropin-releasing hormone. ⁵³ ⁶²	Freda PU...Goland RS	7891545	1995
7	A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. ⁵³ ⁶²	Trainer PJ...Grossman AB	7852498	1995
8	Differential release of proopiomelanocortin-derived peptides from the human pituitary: evidence from a panel of two-site immunoradiometric assays. ⁵³ ⁶²	Gibson S...White A	8157708	1994
9	Hyperfunctioning unilateral adrenal macronodule in three patients with Cushing's disease: hormonal and imaging characterization. ⁵³ ⁶²	Abs R...Beckers A	8237244	1993
10	Cushing's disease and hyperprolactinemia due to a mixed ACTH- and prolactin-secreting pituitary macroadenoma. ⁵³ ⁶²	Mahler C...Trouillas J	1656408	1991
11	Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples. ⁶²	Fleseriu M...Biller BMK	36002784	2022
12	Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. ⁶²	Fleseriu M...Heaney AP	36251618	2022
13	Efficacy and safety of osilodrostat in paraneoplastic Cushing's syndrome: a real-world multicenter study in France. ⁶²	Dormoy A...Young J	36470583	2022
14	Exoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a retrospective single-center study on 388 patients. ⁶²	Sumislawski P...Rotermund R	36136255	2022
15	Genetics of hyperaldosteronism and a wealth of new information on topics ranging from MEN1 to Cushing's disease and metabolic syndrome. ⁶²	Stratakis CA	36380266	2022
16	Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN. ⁶²	Valassi E...Reincke M	36197784	2022
17	Pregnancy after pituitary surgery does not influence the recurrence of Cushing's disease. ⁶²	Lousada LM...Machado MC	35930216	2022
18	Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2). ⁶²	Fleseriu M...Pivonello R	36219274	2022
19	Dynamic testing for differential diagnosis of ACTH-dependent Cushing Syndrome: a systematic review and meta-analysis. ⁶²	Ceccato F...Scaroni C	36453141	2022
20	Problem-solving therapy can reduce psychological distress in patients with Cushing's disease: a randomized controlled trial. ⁶²	Sulu C...Kadioglu P	36050587	2022
21	Increased Risk of Ocular Hypertension in Patients With Cushing's Disease. ⁶²	Ma Y...Zhao Y	35980841	2022
22	Genetic drivers of Cushing's disease: Frequency and associated phenotypes. ⁶²	Hernandez-Ramirez LC...Stratakis CA	36149413	2022
23	Corticotroph tumor progression speed after adrenalectomy. ⁶²	Bessiene L...Assie G	36206174	2022
24	Management of Nelson's Syndrome. ⁶²	Fountas A...Karavitaki N	36363537	2022
25	Correction of Hypercortisolemia with an Improved Cognitive Function and Muscle Mass after Transsphenoidal Surgery in an Older Patient with Cushing's Disease. ⁶²	Terayama R...Yokote K	35491128	2022
26	New hope for a tumor-directed therapy fOR Cushing's disease. ⁶²	Tritos NA	36378569	2022
27	Corticotroph cell hyperplasia as a rare cause of ACTH-dependent Cushing syndrome. ⁶²	Ferri J...Real JT	36470644	2022
28	Plurihormonal pituitary adenoma cosecreting ACTH and GH: a rare cause of Cushing's disease. ⁶²	Amir J...Garfield N	36410786	2022
29	Regression of venous thrombus after trans-sphenoidal hypophysectomy for pituitary-dependent hyperadrenocorticism in a dog. ⁶²	Tanaka S...Hara Y	36335913	2022
30	Reoperation for Recurrent and Persistent Cushing's Disease without Visible MRI Findings. ⁶²	Wang B...Bian L	36431325	2022
31	Predictive Value of Early Postoperative Course of Serum Cortisol After Transsphenoidal Surgery for Cushing's Disease. ⁶²	Meier M...Knappe UJ	36084942	2022
32	How best to monitor the specific side effects of medical treatments of Cushing's disease. ⁶²	Castinetti F	36435719	2022
33	Multiple Deep Vein Thromboses After Curative Surgery for Cushing Disease: A Case Presentation and Review. ⁶²	Contento MN...Brutsaert E	36447828	2022
34	11-Oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing's disease. ⁶²	Nowotny HF...Reisch N	36074938	2022
35	New mechanism of Cushing disease revealed. ⁶²	Starling S	36085417	2022
36	Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study. ⁶²	Zamanipoor Najafabadi AH...Biermasz NR	36327151	2022
37	Osilodrostat-induced adrenal insufficiency in a patient with Cushing's disease. ⁶²	Ekladios C...Feghali K	36415717	2022
38	Adrenal Cushing's Syndrome Treated With Preoperative Osilodrostat and Adrenalectomy. ⁶²	Malik RB...Ben-Shlomo A	36447826	2022
39	Is Desmopressin Useful in the Evaluation of Cushing Syndrome? ⁶²	Castinetti F...Lacroix A	36103267	2022
40	Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis. ⁶²	Valizadeh M...Abiri B	35478451	2022
41	Cushing's disease in children: unique features and update on genetics. ⁶²	Stratakis CA	35750967	2022
42	Growth hormone (GH) deficiency and GH replacement therapy in patients previously treated for Cushing's disease. ⁶²	Boguszewski CL	35552989	2022
43	Genetics of Cushing's disease: from the lab to clinical practice. ⁶²	Theodoropoulou M...Reincke M	35852754	2022
44	Role of Radiation in the treatment of Cushing Disease. ⁶²	Katznelson L	35687214	2022
45	Management of the incidental adrenal mass, continued surveillance versus surgical excision: analysis of US claims data on contemporary socio-demographic predictors and peri-operative outcomes. ⁶²	Del Giudice F...Chung BI	36197701	2022
46	The effect of COVID-19 process on patients with endocrinological disease in a pandemic hospital: What happened to the others? ⁶²	Bozkur E...Dogansen SC	36219200	2022
47	Treatment of Cushing's Disease with Pituitary-Targeting Seliciclib. ⁶²	Liu NA...Melmed S	36214832	2022
48	Cushing's disease: adrenal steroidogenesis inhibitors. ⁶²	Pivonello R...Colao A	36036308	2022
49	Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension. ⁶²	Fleseriu M...Biller BMK	35980235	2022
50	Cushing's disease: role of preoperative and primary medical therapy. ⁶²	Castinetti F	35780261	2022

Sources

Genes for Pituitary-Dependent Cushing's Disease

Genes related to Pituitary-Dependent Cushing's Disease (0 elite genes):

(show all 11)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	POMC	Proopiomelanocortin	Protein Coding	17.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8237244 15817922 8616526 (more) 7891545
2	CRH	Corticotropin Releasing Hormone	Protein Coding	16.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8157708 1848486 7891545 (more) 2178536 7852498 17468067
3	SST	Somatostatin	Protein Coding	12.59	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
4	PRL	Prolactin	Protein Coding	11.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10792343 1656408 11095430
5	NR3C1	Nuclear Receptor Subfamily 3 Group C Member 1	Protein Coding	8.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9854680
6	GH1	Growth Hormone 1	Protein Coding	5.48	Novoseek inferred ⁵³	10792343 11095430
7	TRH	Thyrotropin Releasing Hormone	Protein Coding	5.45	DISEASES inferred ¹⁴
8	USP8	Ubiquitin Specific Peptidase 8	Protein Coding	5.21	DISEASES inferred ¹⁴
9	USP48	Ubiquitin Specific Peptidase 48	Protein Coding	4.74	DISEASES inferred ¹⁴
10	MC2R	Melanocortin 2 Receptor	Protein Coding	4.71	DISEASES inferred ¹⁴
11	GHRH	Growth Hormone Releasing Hormone	Protein Coding	4.7	DISEASES inferred ¹⁴

Sources

Variations for Pituitary-Dependent Cushing's Disease

Sources

Expression for Pituitary-Dependent Cushing's Disease

Search GEO for disease gene expression data for Pituitary-Dependent Cushing's Disease.

Sources

Pathways for Pituitary-Dependent Cushing's Disease

Pathways related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

(show all 12)

#	Super pathways	Score	Top Affiliating Genes
1	GPCR downstream signalling ⁶⁶ Show member pathways G alpha (i) signalling events ⁶⁶ G alpha (q) signalling events ⁶⁶ Signaling by GPCR ⁶⁶	13.16	TRH SST POMC MC2R GHRH CRH
2	Signal Transduction ⁶⁶	12.97	USP8 TRH SST POMC NR3C1 MC2R
3	Class A/1 (Rhodopsin-like receptors) ⁶⁶ Show member pathways GPCR ligand binding ⁶⁶ GPCRs, class A rhodopsin-like ⁷⁴ Peptide GPCRs ⁷⁴ Peptide ligand-binding receptors ⁶⁶	12.93	CRH GHRH MC2R POMC SST TRH
4	G-Beta Gamma Signaling ⁶⁴ Show member pathways CRHR Pathway ⁶⁴ GHRH Signaling ⁶⁴	12.25	POMC GHRH GH1 CRH
5	Glucocorticoid receptor regulatory network ⁶¹	11.22	PRL POMC NR3C1
6	G alpha (s) signalling events ⁶⁶ Show member pathways Defective ACTH causes obesity and POMCD ⁶⁶	11.13	POMC MC2R GHRH CRH
7	Growth hormone receptor signaling ⁶⁶ Show member pathways Prolactin receptor signaling ⁶⁶	11.1	PRL GH1
8	Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) ⁷⁴	11	PRL NR3C1
9	Development_Leptin signaling via JAK/STAT and MAPK cascades ²² Show member pathways phospho-PLA2 pathway ⁶⁶	10.95	TRH POMC
10	Serotonin and anxiety ⁷⁴ Show member pathways Serotonin and anxiety-related events ⁷⁴	10.92	POMC CRH
11	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	10.73	PRL POMC
12	Glucocorticoid Pathway (HPA Axis), Pharmacodynamics ⁶⁰	10.1	POMC CRH

Sources

GO Terms for Pituitary-Dependent Cushing's Disease

Cellular components related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	endosome lumen	GO:0031904	8.92	PRL GH1

Biological processes related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	9.9	TRH PRL POMC NR3C1 MC2R GH1
2	positive regulation of insulin-like growth factor receptor signaling pathway	GO:0043568	9.26	GHRH GH1
3	cell-cell signaling	GO:0007267	9.23	TRH SST POMC GHRH